According to the analysis based on hormone receptor status, patients with residual DCIS and hormone receptor-negative (HR−) breast cancer demonstrated a statistically significant decrease in DMFS (p = 0.030) compared to those without residual DCIS (Fig. 3b) but there was not statistical significance in OS (Fig. 3a). This evidence concerns the gene NR4A1 and breast cancer.